Top Markets
#1 Black Phoenix Black Phoenix +367.14%
#2 Islamic Coin Islamic Coin +158.30%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +55.03%
#5 Akedo Akedo +53.15%
#6 Acurast Acurast +38.47%
#7 BasedHype BasedHype +30.07%
#8 Cryptopia Cryptopia +22.42%
#9 Playnance Playnance +19.71%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.34%
Coin of the day
Black Phoenix Black Phoenix
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings, Inc.

AMBS
Clasificación en acciones #41182
Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm,... Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating innovative diagnostic tools and therapeutic solutions. Its primary focus areas encompass neurological disorders, psychiatric conditions, eye-related ailments (ophthalmology), and regenerative medicine. The company's diagnostic pipeline includes the LymPro test, a blood-based diagnostic designed to detect Alzheimer's disease by analyzing lymphocyte proliferation, and MSPrecise, a proprietary DNA sequencing assay aimed at identifying individuals with multiple sclerosis. On the therapeutic front, Amarantus is advancing Eltoprazine, a small molecule drug targeting both Levadopa-Induced Dyskinesia in Parkinson's patients and attention deficit hyperactivity disorders (ADHD). Additionally, they are developing a mesencephalic-astrocyte-derived neurotrophic factor (MANF) for treating conditions modeled in animals, such as retinitis pigmentosa and retinal artery occlusion. Amarantus also maintains several specialized platforms: NuroPro, a diagnostic platform dedicated to neurodegenerative diseases with an initial application in Parkinson's; BC-SeraPro, an oncology diagnostic platform specifically for breast cancer; and the PhenoGuard platform, designed for discovering new neurotrophic factors. Beyond these, the company is progressing with Engineered Skin Substitute (ESS), a cell therapy-based product for autologous skin replacement, currently in mid-stage clinical development for severe, life-threatening burns. The company has established a collaborative research and development agreement with both the U.S. Army Institute of Surgical Research and Rutgers University. Established in 2008, Amarantus BioScience Holdings, Inc., which previously operated as Amarantus Bioscience, Inc. until its name change in April 2013, is headquartered in New York, New York.
Precio por acción
$0.0001
Última sincronización: 2026-08-12
Capitalización bursátil
$36.84K
Cambio (1 día)
0.00%
Cambio (1 año)
-66.67%
País
US
Comercio Amarantus BioScience Holdings, Inc. (AMBS)

Categoría

Healthcare
Ratio P/E de Amarantus BioScience Holdings, Inc. (AMBS)
Ratio P/E al 2026 TTM: 0
Según los últimos informes financieros y el precio de las acciones de Amarantus BioScience Holdings, Inc., el P/E actual (TTM) de la empresa es 0. Al final de 2026, la empresa tenía un P/E de 0.
Historial del ratio P/E de Amarantus BioScience Holdings, Inc. desde 2026 hasta 2026
Relación P/E al final de cada año
Año Ratio P/E Cambiar
Not enough data for the provided dates.
Relación P/E para empresas similares o competidores
Empresa P/E Ratio Diferencia del P/E Ratio País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
¿Cómo leer un P/E ratio?

El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.

Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.

Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.